<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04815213</url>
  </required_header>
  <id_info>
    <org_study_id>POF.UJCTC</org_study_id>
    <nct_id>NCT04815213</nct_id>
  </id_info>
  <brief_title>The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans</brief_title>
  <official_title>The Use of Expanded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans: Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous bone marrow-derived mesenchymal cells will be injected into patients diagnosed&#xD;
      with premature ovarian failure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MSCs in passage-2 culture will be washed with PBS and detached with trypsin/EDTA (0.25%).&#xD;
      After that, the cells will be suspended at a density of 20×106 cells/ 2 ml normal saline and&#xD;
      loaded into 3 ml sterile syringes.&#xD;
&#xD;
      The cells should be infused within 2 hours of release. Tests and follow up are to be monthly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment adverse events are defined by any adverse event leading to hospitalization, organ failure or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with enhanced hormonal profile, ovarian changes and endometrial changes</measure>
    <time_frame>12 months</time_frame>
    <description>Efficacy will be measured comparing hormonal changes (FSH, LH, AMH, estradiol) in patients' blood on monthly intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with positive ovarian changes</measure>
    <time_frame>12 months</time_frame>
    <description>Patients ultrasounds of the ovaries will compare size and follicle numbers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with increased endometrial thickness</measure>
    <time_frame>12 months</time_frame>
    <description>Ultrasounds of uterus will be compared for endometrial thickness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expanded autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>expanded autologous bone marrow derived MSC</intervention_name>
    <description>Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>BM-MSc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent&#xD;
&#xD;
          2. Married female, 18-38 years old&#xD;
&#xD;
          3. Diagnosis of premature ovarian insufficiency: At least two menopausal FSH levels (≥ 20&#xD;
             IU/L) and/or Primary or secondary amenorrhea at least for 6 months&#xD;
&#xD;
          4. Evidence of low ovarian reserve defined as: AMH &lt; _0.3 ng/ML &amp; FSH &gt;20 IU/L, AFC &lt; 4,&#xD;
             and/or failure of prior attempts of assisted reproductive techniques due to limited&#xD;
             ovarian response (poor responder).&#xD;
&#xD;
          5. Normal karyotype 46, XX.&#xD;
&#xD;
          6. Presence of at least one ovary&#xD;
&#xD;
          7. Normal thyroid function as evidence by normal serum Thyroid Stimulating Hormone (TSH)&#xD;
             levels.&#xD;
&#xD;
          8. Agree to report any pregnancy to the research staff immediately.&#xD;
&#xD;
          9. Cooperative patient&#xD;
&#xD;
         10. Negative for infectious panel (HIV, HBV, HCV, and VDRL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently breast-feeding&#xD;
&#xD;
          2. Has a history of, or evidence of current malignancy&#xD;
&#xD;
          3. Major mental health disorder that precludes participation in the study&#xD;
&#xD;
          4. Current or recent (within the past 2 weeks) use of the following medications: Oral or&#xD;
             systemic corticosteroids, Hormones (estrogen, progestins, oral contraceptives),&#xD;
             Danazol, anticoagulants, herbal or botanical supplements with possible hormonal&#xD;
             effects. Washout will be allowed.&#xD;
&#xD;
          5. Type I or Type II diabetes mellitus, or if receiving antidiabetic medications&#xD;
&#xD;
          6. Significant anemia (Hemoglobin &lt;8 g/dL).&#xD;
&#xD;
          7. Untreated deep venous thrombosis, and/or pulmonary embolus&#xD;
&#xD;
          8. Known heart disease (New York Heart Association Class II or higher).&#xD;
&#xD;
          9. Known Liver disease (defined as Aspartate Aminotransferase (AST) or Alanine&#xD;
             Aminotransferase (ALT)&gt;2 times normal, or total bilirubin &gt;2.5 mg/dL).&#xD;
&#xD;
         10. Known Renal disease (defined as Blood urea nitrogen (BUN)&gt;30 mg/dL or serum creatinine&#xD;
             &gt; 1.6 mg/dL).&#xD;
&#xD;
         11. Clinically active autoimmune condition&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Married female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Abdalla Awidi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cell therapy center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Hanan Jafar, PhD</last_name>
    <phone>+96798871087</phone>
    <email>hanan.jafar@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cell Therapy Center, University of Jordan</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdullah Aweidi, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Hanan Jafar</investigator_full_name>
    <investigator_title>Vice director/ Cell therapy center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

